Stockwell Lynn's Form 4 filing
Drugs Made In America Acquisition Corp. (DMAA) · filed Feb 18, 2025
- Accession no.
- 0001213900-25-015019
- Filed
- Feb 18, 2025
- Trade date
- Feb 18, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stockwell LynnCIK 0001927032 | Director, Officer (CEO and Exe. Chair of Board), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | Ordinary shares | PPurchaseAcquired | +30,000 | – | – | 4,188,780 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | Ordinary shares | PPurchaseAcquired | +30,000 | – | – | 430,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.